ethnic-bridging-995x60.png ethnic-bridging-995x60.png

FEATURED ARTICLES

Singapore Reduces Risks To Life Sciences Entering The Asian Market

There are many risks involved with opening pharmaceutical manufacturing operations in Asia, but Signapore has become ideal for the Life Sciences industry.

  • Considerations In Using Foreign Trial Data In U.S. NDA Submissions

    More and more drug companies are finding it financially advantageous to conduct clinical trials in foreign countries and to include data from these trials in NDA submissions. When offshore trials are properly conducted and the data is properly handled, this strategy can accelerate approval and lower the cost of drug development. By Ken Phelps, Camargo Pharmaceutical Services

  • The Business Of Cultural Competent Research: The New Stakeholders

    For industry committed to delivering innovative healthcare, now is the time to take stock of the shift in population demographics and how cultural competence relates to developing new medicines through clinical trials. By James Gillespie and Kathleen Drennan

  • rob
    Want To Increase Clinical Trial Participation? I recently read an article about drug companies paying hospitals to mine their databases for potential clinical trial participants. Apparently, drug companies, including Pfizer (NYSE: PFE), are willing to pay somewhere between $50,000 to $200,000 per list of patients qualifying for drugmaker clinical trials. By Rob Wright, Chief Editor, Life Science Leader magazine
More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Ethnic Bridging

    Clinilabs, a contract research organization (CRO), was selected to characterize the pharmacokinetic prole of XXXX following the administration of four doses of XXXX to healthy Japanese and non-Japanese subjects aged 20 to 45 years by assessing serum concentration data over time.

  • White Paper: Foreign Clinical Trial Data Given the high cost of moving a promising drug candidate through years of clinical trials, it’s no wonder that more and more drug manufacturers have begun conducting at least some of their clinical trials in foreign countries. With lower costs and shorter recruiting times, the use of foreign sites is appealing to all drug developers, but especially to those involved in generic and “fast-track” approval programs.
More White Papers & Case Studies

NEWS

More News